Brokerage firm Northcoast Research Upgrades its rating on Wright Medical Group Inc(WMGI). The shares have been rated Buy. Previously, the analysts had a Neutral rating on the shares. The rating by the stock financial advisor at Northcoast Research was issued on Mar 21, 2017 in a research report to their Investors and Clients.
In a different note, On Feb 15, 2017, Needham said it Downgrades its rating on Wright Medical Group Inc. The shares have been rated ‘Hold’ by the firm. On Jan 3, 2017, Guggenheim said it Downgrades its rating on Wright Medical Group Inc. The shares have been rated ‘Neutral’ by the firm.
Wright Medical Group Inc (WMGI) made into the market gainers list on Fridays trading session with the shares advancing 2.04% or 0.62 points. Due to strong positive momentum, the stock ended at $31.06, which is also near the day’s high of $31.31. The stock began the session at $30.5 and the volume stood at 13,48,602 shares. The 52-week high of the shares is $31.31 and the 52 week low is $15.52. The company has a current market capitalization of $3,219 M and it has 10,36,25,395 shares in outstanding.
Wright Medical Group Inc(WMGI) last announced its earnings results on Feb 21, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $193.023M. Analysts had an estimated revenue of $183.590M. Earnings per share were $-0.06. Analysts had estimated an EPS of $-0.11.
Several Insider Transactions has been reported to the SEC. On Mar 7, 2017, John L Miclot (director) sold 20,618 shares at $28.50 per share price.Also, On Feb 28, 2017, David D Stevens (director) sold 11,807 shares at $28.01 per share price.On Feb 9, 2017, Richard F Wallman (director) sold 9,000 shares at $26.25 per share price, according to the Form-4 filing with the securities and exchange commission.
Wright Medical Group Inc. is a global specialty orthopaedic company. The Company through Wright Medical Technology Inc. (WMT) and other subsidiaries provides extremity and biologic solutions that enable clinicians to alleviate pain and restore the patients’ lifestyles. The Company operates through three segments: U.S. International and BioMimetic. The Company’s business includes products that are used in foot and ankle repair upper extremity products and biologics products which are used to replace damaged or diseased bone to stimulate bone growth and to provide other biological solutions for surgeons and patients. The Company’s products include extremity hardware foot and ankle hardware upper extremity hardware and biologics.